Genomically Matched Therapy Improves Response and PFS Across Advanced Solid Tumors: Phase 2 ROME Trial
Highlights
– The ROME randomized phase 2 trial (NCT04591431) demonstrated a higher overall response rate (17.5% vs 10%, P=0.0294) and improved median progression-free survival (3.5 vs 2.8 months; HR 0.66, P=0.0002) for genomically matched, MTB-guided therapy (TT) versus standard of care (SoC) in patients with advanced solid tumors after 1–2 prior lines of therapy.
– TT produced superior 12-month PFS (22.0% vs 8.3%) with similar grade 3–4 adverse event rates (40% TT vs 52% SoC). Median overall survival was similar, likely confounded by a 52% crossover rate.
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.